Lipella Pharmaceuticals Inc. (LIPO) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.05
↓-98% vs avg
5yr avg: 2.11
30Y Low1.7·High2.7
ROE
↓
-198.1%
↑-56% vs avg
5yr avg: -127.0%
30Y Low-198%·High-36%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LIPO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lipella Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $377577 | $3M | $6M | $13M | — | — | — |
| Enterprise Value | $-1759681 | $1M | $3M | $8M | — | — | — |
| P/E Ratio → | -0.02 | — | — | — | — | — | — |
| P/S Ratio | 0.70 | 5.96 | 13.62 | 69.02 | — | — | — |
| P/B Ratio | 0.05 | 1.67 | 1.95 | 2.72 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LIPO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.98 | 6.60 | 43.54 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
LIPO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lipella Pharmaceuticals Inc. earns an operating margin of -947.2%. Operating margins have expanded from -1406.3% to -947.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -198.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -573.7% | -573.7% | -575.9% | -1283.4% | -461.7% | -1.5% | 1.7% |
| Operating Margin | -947.2% | -947.2% | -1055.6% | -1406.3% | -738.7% | -5.9% | -7.7% |
| Net Profit Margin | -935.2% | -935.2% | -1027.3% | -1410.6% | -719.3% | -6.4% | -8.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -198.1% | -118.1% | -85.2% | -197.7% | -35.7% | — |
| ROA | -160.5% | -160.5% | -97.0% | -65.2% | -125.7% | -11.5% | -52.0% |
| ROIC | — | — | — | -1407.2% | -534.0% | -42.4% | — |
| ROCE | -198.8% | -198.8% | -119.2% | -80.4% | -158.4% | -16.2% | — |
LIPO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $47605, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.04 | 0.09 | 0.20 | 0.84 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.11 | -1.00 | -1.00 | -0.79 | -0.47 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -424.79 | -269.26 | -271.97 | -6.74 | -6.41 |
Net cash position: cash ($2M) exceeds total debt ($47605)
LIPO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lipella Pharmaceuticals Inc.'s current ratio of 3.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.92x to 3.47x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.47 | 3.47 | 8.90 | 4.92 | 5.31 | 3.37 | 0.72 |
| Quick Ratio | 3.47 | 3.47 | 8.90 | 4.92 | 5.31 | 3.37 | 0.72 |
| Cash Ratio | 2.90 | 2.90 | 8.55 | 4.35 | 5.03 | 2.92 | 0.16 |
| Asset Turnover | — | 0.20 | 0.13 | 0.03 | 0.13 | 1.01 | 5.84 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 57.65 | 26.21 | 225.27 | — | 26.20 | 44.07 |
LIPO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lipella Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $1M | $750384 | $507578 | $426006 | $266400 | $260000 |
Peer Comparison
Compare LIPO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LIPOYou | $377577 | -0.0 | — | — | -573.7% | -947.2% | -198.1% | — | — |
 SIGA | $308M | 13.0 | 6.3 | 7.2 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 INVA | $2B | 7.1 | 7.1 | 8.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $9B | -22.7 | — | — | — | — | -45.8% | -65.0% | — |
 ALDX | $122M | -3.6 | — | — | — | — | -58.7% | -245.8% | — |
 RCKT | $379M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 HALO | $8B | 27.2 | 11.4 | 12.8 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 PHAT | $863M | -3.6 | — | — | 87.1% | -91.4% | — | — | — |
 ABBV | $415B | 99.1 | 17.0 | 23.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $141B | 18.2 | 10.2 | 15.5 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.0 | 14.1 | 18.7 | 63.6% | -4.8% | -32.4% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
LIPO — Frequently Asked Questions
Quick answers to the most common questions about buying LIPO stock.
What is Lipella Pharmaceuticals Inc.'s P/E ratio?
Lipella Pharmaceuticals Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Lipella Pharmaceuticals Inc.'s ROE?
Lipella Pharmaceuticals Inc.'s return on equity (ROE) is -198.1%. The historical average is -127.0%.
Is LIPO stock overvalued?
Based on historical data, Lipella Pharmaceuticals Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Lipella Pharmaceuticals Inc.'s profit margins?
Lipella Pharmaceuticals Inc. has -573.7% gross margin and -947.2% operating margin.